High-Risk Coronavirus Disease 2019 Patient Criteria per the Food and Drug Administration Emergency Use Authorization Fact Sheets for Bamlanivimab and Casirivimab/Imdevimab
| Age ≥65 y |
| BMI ≥35 kg/m2 |
| Diabetes |
| Chronic kidney disease |
| Immunosuppressant disease or treatment |
| Age ≥55 y AND have 1 of the following: |
| • Hypertension |
| • Chronic respiratory disease/chronic obstructive pulmonary disease |
| • Cardiovascular disease |
| Age 12–17 y AND have 1 of the following: |
| • BMI ≥85th percentile for age and gender |
| • Sickle cell disease |
| • Congenital or acquired heart disease |
| • Neurodevelopmental disorder, eg, cerebral palsy |
| • Medical-related technological dependence, eg, tracheostomy, gastrostomy, or positive-pressure ventilations (not related to COVID-19) |
| • Asthma, reactive airway, or other chronic respiratory disease that requires daily medication control |
| Age ≥65 y |
| BMI ≥35 kg/m2 |
| Diabetes |
| Chronic kidney disease |
| Immunosuppressant disease or treatment |
| Age ≥55 y AND have 1 of the following: |
| • Hypertension |
| • Chronic respiratory disease/chronic obstructive pulmonary disease |
| • Cardiovascular disease |
| Age 12–17 y AND have 1 of the following: |
| • BMI ≥85th percentile for age and gender |
| • Sickle cell disease |
| • Congenital or acquired heart disease |
| • Neurodevelopmental disorder, eg, cerebral palsy |
| • Medical-related technological dependence, eg, tracheostomy, gastrostomy, or positive-pressure ventilations (not related to COVID-19) |
| • Asthma, reactive airway, or other chronic respiratory disease that requires daily medication control |
Source: Food and Drug Administration [7, 8].
Abbreviations: BMI, body mass index; COVID-19, coronavirus disease 2019.
High-Risk Coronavirus Disease 2019 Patient Criteria per the Food and Drug Administration Emergency Use Authorization Fact Sheets for Bamlanivimab and Casirivimab/Imdevimab
| Age ≥65 y |
| BMI ≥35 kg/m2 |
| Diabetes |
| Chronic kidney disease |
| Immunosuppressant disease or treatment |
| Age ≥55 y AND have 1 of the following: |
| • Hypertension |
| • Chronic respiratory disease/chronic obstructive pulmonary disease |
| • Cardiovascular disease |
| Age 12–17 y AND have 1 of the following: |
| • BMI ≥85th percentile for age and gender |
| • Sickle cell disease |
| • Congenital or acquired heart disease |
| • Neurodevelopmental disorder, eg, cerebral palsy |
| • Medical-related technological dependence, eg, tracheostomy, gastrostomy, or positive-pressure ventilations (not related to COVID-19) |
| • Asthma, reactive airway, or other chronic respiratory disease that requires daily medication control |
| Age ≥65 y |
| BMI ≥35 kg/m2 |
| Diabetes |
| Chronic kidney disease |
| Immunosuppressant disease or treatment |
| Age ≥55 y AND have 1 of the following: |
| • Hypertension |
| • Chronic respiratory disease/chronic obstructive pulmonary disease |
| • Cardiovascular disease |
| Age 12–17 y AND have 1 of the following: |
| • BMI ≥85th percentile for age and gender |
| • Sickle cell disease |
| • Congenital or acquired heart disease |
| • Neurodevelopmental disorder, eg, cerebral palsy |
| • Medical-related technological dependence, eg, tracheostomy, gastrostomy, or positive-pressure ventilations (not related to COVID-19) |
| • Asthma, reactive airway, or other chronic respiratory disease that requires daily medication control |
Source: Food and Drug Administration [7, 8].
Abbreviations: BMI, body mass index; COVID-19, coronavirus disease 2019.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
